caption
stringlengths
0
3.92k
molecule
stringlengths
1
914
properties
listlengths
1
113
additional_data
dict
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, cholesterol translocation that impacts barth syndrome and aging. The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts diabetic heart disease, non-alcoholic fatty liver disease, and tangier disease.
CCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCC(C)C
[ "Stabilizing mitochondrial structure", "Barth syndrome", "Proton trap for oxidative phosphorylation", "Aging", "Cholesterol translocation", "Diabetic heart disease", "Non-alcoholic fatty liver disease", "Stabilizing cytochrome oxidase", "Tangier disease", "Apoptosis" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing mitochondrial structure, cholesterol translocation, apoptosis that impacts aging and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, tangier disease, and barth syndrome.
CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C
[ "Stabilizing mitochondrial structure", "Aging", "Cholesterol translocation", "Apoptosis", "Non-alcoholic fatty liver disease", "Stabilizing cytochrome oxidase", "Diabetic heart disease", "Tangier disease", "Barth syndrome", "Proton trap for oxidative phosphorylation" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a nutrient, fat storage, inflammatory, energy storage that impacts atherosclerosis and pancreatitis. The molecule is a energy source that impacts both obesity and cardiovascular disease. The molecule is a membrane stabilizer that affects cancer by impacting both metabolic syndrome and thyroxine treatmen...
CCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C
[ "nutrient", "Atherosclerosis", "Fat storage", "inflammatory", "Pancreatitis", "Energy storage", "Obesity", "Energy source", "Cardiovascular disease", "Metabolic syndrome", "Thyroxine treatment", "Membrane stabilizer", "Cancer" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a egfr inhibitor.
CC1CC(C)C(S)C(C)C1
[ "egfr inhibitor" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
It impacts pancreatitis, cardiovascular disease, and thyroxine treatment. The molecule is a nutrient and a fat storage, impacting both atherosclerosis and metabolic syndrome.
CCCCCCCC/C=C\CCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCC
[ "Pancreatitis", "Cardiovascular disease", "Thyroxine treatment", "Atherosclerosis", "Metabolic syndrome", "nutrient", "Fat storage" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a nutrient.
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](N)C(=O)O)OC(=O)CCC[C@@H](O)[C@H](O)C/C=C\C/C=C\C/C=C\C/C=C\CC
[ "nutrient" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a apoptosis, a stabilizing cytochrome oxidase, a energy storage, and smooth. The molecule is a food additive that impacts tangier disease, aging, diabetic heart disease, and non-alcoholic fatty liver disease. The molecule is a surfactant, a cholesterol translocation, and a energy source, and it impacts ...
CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC
[ "Apoptosis", "Smooth", "Stabilizing cytochrome oxidase", "Energy storage", "Tangier disease", "Aging", "Diabetic heart disease", "Non-alcoholic fatty liver disease", "food additive", "surfactant", "Barth syndrome", "Cholesterol translocation", "Energy source", "Emulsifier", "Proton trap ...
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
It impacts insulin resistance.
CCCCC/C=C\C/C=C\CCCCCCCCCCCC(=O)OC[C@H](O)COC(=O)CCCCCCCCCCCCCCC
[ "Insulin resistance" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a cancer treatment.
CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NS(=O)c3ccc(Br)c(Br)c3)cc2C(=O)N2Cc3ccccc3CC2CO)n1
[ "cancer treatment" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a cholesterol translocation that impacts diabetic heart disease, non-alcoholic fatty liver disease, barth syndrome, and aging. The molecule is a apoptosis, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts tangier disease.
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC
[ "Diabetic heart disease", "Non-alcoholic fatty liver disease", "Barth syndrome", "Aging", "Cholesterol translocation", "Apoptosis", "Tangier disease", "Stabilizing cytochrome oxidase", "Proton trap for oxidative phosphorylation", "Stabilizing mitochondrial structure" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a anti bacterial.
COc1noc2c(F)c3c(cc12)CC1(C(=O)NC(=O)NC1=O)C1C(C)OCCN31
[ "anti bacterial" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
It belongs to the organic light-emitting device class of molecules.
N#Cc1ccc(-n2c3ccccc3c3cc(-n4c5ccccc5c5ccccc54)ccc32)c(-c2ccc(-n3c4ccccc4c4cc(C#N)ccc43)cc2C#N)c1
[ "organic light-emitting device" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a protein kinase inhibitor, btk inhibitor, kinase inhibitor, cancer treatment, and inflammation treatment.
C=CC(=O)N1CCCC(c2nn(-c3ccc(Oc4cccc(F)c4F)cc3)c3c(N)n[nH]c(=O)c23)C1
[ "protein kinase inhibitor", "btk inhibitor", "kinase inhibitor", "inflammation treatment", "cancer treatment" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a hypoglycemic agent, a insulinotonic, and a insulinase inhibitor, it impacts schizophrenia and is pharmaceutical.
C[C@@H]1O[C@@H](O[C@H]2[C@@H](O)[C@@H](CO)O[C@@H](O[C@H]3[C@H](O)[C@@H](O)C(O)O[C@@H]3CO)[C@@H]2O)[C@@H](O)[C@H](O)[C@@H]1O
[ "hypoglycemic agent", "Schizophrenia", "Pharmaceutical", "insulinotonic", "insulinase inhibitor" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is anti microbial, anti psychotic, and anti parasitic.
CC(=O)OC1OC(COC(=O)C(OC(C)C)=C(C)C(C)C)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O
[ "anti microbial", "anti psychotic", "anti parasitic" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing mitochondrial structure and a cholesterol translocation that impacts tangier disease, aging, and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, apoptosis that impacts barth syndrome and diabetic heart disease.
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC
[ "Stabilizing mitochondrial structure", "Tangier disease", "Aging", "Cholesterol translocation", "Non-alcoholic fatty liver disease", "Barth syndrome", "Proton trap for oxidative phosphorylation", "Stabilizing cytochrome oxidase", "Apoptosis", "Diabetic heart disease" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
It belongs to both the anti oxidant and anti inflammatory classes of molecules.
CN(C)CCNc1nc(NCc2ccco2)c2ncn(C3CCCCO3)c2n1
[ "anti oxidant", "anti inflammatory" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a cholesterol translocation and a stabilizing cytochrome oxidase that impacts barth syndrome, diabetic heart disease, and tangier disease. The molecule is a proton trap for oxidative phosphorylation, apoptosis, stabilizing mitochondrial structure that impacts aging and non-alcoholic fatty liver disease.
CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCC(C)C
[ "Barth syndrome", "Cholesterol translocation", "Diabetic heart disease", "Tangier disease", "Stabilizing cytochrome oxidase", "Proton trap for oxidative phosphorylation", "Apoptosis", "Stabilizing mitochondrial structure", "Aging", "Non-alcoholic fatty liver disease" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, cholesterol translocation that impacts diabetic heart disease and barth syndrome. The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts aging, tangier disease, and non-alcoholic fatty liver disease.
CCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCC
[ "Stabilizing mitochondrial structure", "Diabetic heart disease", "Proton trap for oxidative phosphorylation", "Cholesterol translocation", "Barth syndrome", "Aging", "Stabilizing cytochrome oxidase", "Tangier disease", "Apoptosis", "Non-alcoholic fatty liver disease" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a food additive, a apoptosis, and a stabilizing cytochrome oxidase, and it impacts barth syndrome. The molecule is a energy storage, emulsifier, stabilizing mitochondrial structure, membrane stabilizer, and smooth. The molecule is a proton trap for oxidative phosphorylation and a surfactant, impacting b...
CCC(C)CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCC(C)C
[ "food additive", "Apoptosis", "Stabilizing cytochrome oxidase", "Barth syndrome", "Energy storage", "Emulsifier", "Stabilizing mitochondrial structure", "Membrane stabilizer", "Smooth", "Proton trap for oxidative phosphorylation", "Non-alcoholic fatty liver disease", "surfactant", "Diabetic ...
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is light-emitting and phosphorescent.
CC#N.CCCCOC(C)=O.Cc1ccccc1
[ "light-emitting", "phosphorescent" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a nutrient that affects breast cancer by impacting cervical cancer, ulcerative colitis, and atherosclerosis.
CCCCC/C=C\C/C=C\CCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCC/C=C\C/C=C\C/C=C\CC1OC1CCCCC
[ "Cervical cancer", "Breast cancer", "Ulcerative colitis", "Atherosclerosis", "nutrient" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts barth syndrome, non-alcoholic fatty liver disease, and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, cholesterol translocation that impacts aging and tangier disease.
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC
[ "Barth syndrome", "Non-alcoholic fatty liver disease", "Diabetic heart disease", "Apoptosis", "Stabilizing cytochrome oxidase", "Aging", "Proton trap for oxidative phosphorylation", "Stabilizing mitochondrial structure", "Tangier disease", "Cholesterol translocation" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
It impacts heart failure, renal cell carcinoma, celiac disease, and diabetes mellitus type 2. The molecule is a energy source that affects breast cancer by impacting both cardiovascular disease and inflammatory bowel disease.
CCCCCC=CCC(O)CCCCCCCCCCCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C
[ "Heart failure", "Renal cell carcinoma", "Celiac disease", "Diabetes mellitus type 2", "Energy source", "Breast cancer", "Cardiovascular disease", "Inflammatory bowel disease" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a nutrient.
CC(C)C1NC(=O)C(NC(=O)C(Cc2ccc(O)cc2)NC(=O)C2CCCN2C(=O)C2CCC(=O)N2)n2cc(c3ccccc32)CC(C(=O)O)NC(=O)C(CO)NC(=O)C(Cc2ccccc2)NC1=O
[ "nutrient" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
It influences both colorectal cancer and stomach cancer, as well as affecting cardiovascular disease and breast cancer. It impacts alzheimer's disease, parkinson's disease, seizure, and diabetes mellitus.
CCCCC/C=C\C/C=C\CCCCCCCCCCCC(=O)O[C@@H]1COC(=O)CCC/C=C/C[C@@H]2[C@@H](O)[C@H](O)[C@@H](O)[C@H](OP(=O)(O)OC1)[C@H](OP(=O)(O)O)[C@H](O)[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]2O
[ "Cardiovascular disease", "Colorectal cancer", "Breast cancer", "Stomach cancer", "Alzheimer's Disease", "Parkinson's disease", "Seizure", "Diabetes mellitus" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a nutrient, inflammatory, fat storage, energy source that impacts pancreatitis and metabolic syndrome. The molecule is a energy storage that impacts both atherosclerosis and cardiovascular disease. The molecule is a membrane stabilizer belonging to the thyroxine treatment class, known to affect cancer a...
CCC(C)CCCCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCCCC(C)C
[ "Pancreatitis", "nutrient", "inflammatory", "Fat storage", "Metabolic syndrome", "Energy source", "Atherosclerosis", "Cardiovascular disease", "Energy storage", "Membrane stabilizer", "Thyroxine treatment", "Obesity", "Cancer" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a nutrient that impacts alzheimer's disease, non-alcoholic fatty liver disease, parkinson's disease, and diabetes mellitus type 2.
CCCCC/C=C\C[C@H](O)/C=C/C=C\C/C=C\CCCC(=O)O[C@H](CO/C=C/CCCCCCCCCCCCCC)COP(=O)(O)OCCN
[ "Alzheimer's Disease", "nutrient", "Non-alcoholic fatty liver disease", "Parkinson's disease", "Diabetes mellitus type 2" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a pim kinase inhibitor and belongs to the cancer treatment class of molecules.
Cc1ccnc2c(C(=O)Nc3cnccc3N3CCCC(N)C3)c(N)oc12
[ "cancer treatment", "pim kinase inhibitor" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a membrane stabilizer, nutrient, energy storage, inflammatory that impacts obesity and atherosclerosis. The molecule is a energy source, a thyroxine treatment, and a fat storage. It impacts cancer, metabolic syndrome, cardiovascular disease, and pancreatitis.
CCCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCC
[ "Membrane stabilizer", "nutrient", "Energy storage", "inflammatory", "Obesity", "Atherosclerosis", "Energy source", "Thyroxine treatment", "Fat storage", "Cancer", "Metabolic syndrome", "Cardiovascular disease", "Pancreatitis" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a anti viral and belongs to the anti allergic class of molecules.
CCCCC(=O)Nc1ccc(CC(=O)OCCC)s1
[ "anti allergic", "anti viral" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a nutrient.
O=C(OC1Cc2cc(O)c(O)cc2OC1c1ccc(O)c(O)c1)c1cc(O)c(=O)c2c(O)c(O)cc(C3Oc4cc(O)cc(O)c4CC3O)c2c1
[ "nutrient" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a fat storage and nutrient, and it impacts pancreatitis. The molecule is a member of the thyroxine treatment class and affects atherosclerosis, cardiovascular disease, and metabolic syndrome.
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC
[ "Fat storage", "Pancreatitis", "nutrient", "Atherosclerosis", "Thyroxine treatment", "Cardiovascular disease", "Metabolic syndrome" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a emulsifier, a apoptosis, and a energy source, and it impacts barth syndrome. The molecule is a surfactant, stabilizing cytochrome oxidase, cholesterol translocation that impacts tangier disease and non-alcoholic fatty liver disease. The molecule is a membrane stabilizer, a food additive, a energy stor...
CCC(C)CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C
[ "Emulsifier", "Barth syndrome", "Apoptosis", "Energy source", "surfactant", "Tangier disease", "Stabilizing cytochrome oxidase", "Cholesterol translocation", "Non-alcoholic fatty liver disease", "Smooth", "Membrane stabilizer", "food additive", "Energy storage", "Aging", "Nutritional sup...
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a anti tumor.
CC(C)c1cnc(NC(=O)Cc2ccc(NC(=O)Cn3nnc(N4CCCC4)n3)cc2)s1
[ "anti tumor" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing mitochondrial structure, cholesterol translocation, stabilizing cytochrome oxidase that impacts aging and diabetic heart disease. The molecule is a apoptosis and a proton trap for oxidative phosphorylation that impacts barth syndrome, tangier disease, and non-alcoholic fatty liver disease.
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC
[ "Aging", "Stabilizing mitochondrial structure", "Cholesterol translocation", "Stabilizing cytochrome oxidase", "Diabetic heart disease", "Barth syndrome", "Apoptosis", "Tangier disease", "Non-alcoholic fatty liver disease", "Proton trap for oxidative phosphorylation" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a cholesterol translocation, a energy storage, and a nutritional supplement, and it impacts diabetic heart disease. The molecule is a membrane stabilizer, energy source, surfactant, stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative...
CCC(C)CCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCC(C)C
[ "Cholesterol translocation", "Energy storage", "Diabetic heart disease", "Nutritional supplement", "Membrane stabilizer", "Non-alcoholic fatty liver disease", "Energy source", "surfactant", "Stabilizing cytochrome oxidase", "Smooth", "Tangier disease", "Proton trap for oxidative phosphorylatio...
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is floral, sweet, and woody.
COc1cc(/C=C/C(=O)O[C@H]2CC[C@@]3(C)C(=CCC4C3CC[C@@]3(C)C4CC[C@@H]3[C@H](C)CCC(C)C(C)C)C2)ccc1O
[ "floral", "sweet", "woody" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a energy storage, a stabilizing mitochondrial structure, and a food additive, and it impacts aging. The molecule is a nutritional supplement, apoptosis, energy source that impacts non-alcoholic fatty liver disease and barth syndrome. The molecule is a membrane stabilizer, a stabilizing cytochrome oxidas...
CCC(C)CCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C
[ "Energy storage", "Aging", "Stabilizing mitochondrial structure", "food additive", "Non-alcoholic fatty liver disease", "Nutritional supplement", "Barth syndrome", "Apoptosis", "Energy source", "Membrane stabilizer", "Stabilizing cytochrome oxidase", "Smooth", "surfactant", "Diabetic heart...
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a flavoring agent, citrus, metallic, aldehydic, waxy. The molecule is fresh, coumarinic, and moss; additionally, it is amber and tuberose.
CCCCC/C=C1/CCCC1=O
[ "citrus", "Flavoring agent", "metallic", "aldehydic", "waxy", "fresh", "coumarinic", "moss", "amber", "tuberose" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a energy source, membrane stabilizer, nutrient that belongs to the thyroxine treatment class of molecules and impacts both cardiovascular disease and atherosclerosis. The molecule is a energy storage that affects cancer by impacting pancreatitis. The molecule is a inflammatory and a fat storage, impacti...
CCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCC(C)C
[ "Energy source", "Cardiovascular disease", "Thyroxine treatment", "Membrane stabilizer", "nutrient", "Atherosclerosis", "Pancreatitis", "Energy storage", "Cancer", "Obesity", "Metabolic syndrome", "inflammatory", "Fat storage" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a nutritional supplement that impacts diabetic heart disease, aging, and non-alcoholic fatty liver disease. The molecule is a emulsifier, cholesterol translocation, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, energy source. The molecule is a surfactant and a energy st...
CCC(C)CCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)C
[ "Nutritional supplement", "Diabetic heart disease", "Aging", "Non-alcoholic fatty liver disease", "Emulsifier", "Cholesterol translocation", "Stabilizing mitochondrial structure", "Proton trap for oxidative phosphorylation", "Energy source", "surfactant", "Tangier disease", "Barth syndrome", ...
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a nutrient that impacts alzheimer's disease, diabetes mellitus type 2, non-alcoholic fatty liver disease, and parkinson's disease.
CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\C=C\C(=O)CCCCC)COP(=O)(O)OCCN
[ "nutrient", "Alzheimer's Disease", "Diabetes mellitus type 2", "Non-alcoholic fatty liver disease", "Parkinson's disease" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing mitochondrial structure, apoptosis, proton trap for oxidative phosphorylation that impacts tangier disease and aging. The molecule is a cholesterol translocation and a stabilizing cytochrome oxidase that impacts diabetic heart disease, non-alcoholic fatty liver disease, and barth syndrome.
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC
[ "Tangier disease", "Stabilizing mitochondrial structure", "Apoptosis", "Aging", "Proton trap for oxidative phosphorylation", "Cholesterol translocation", "Diabetic heart disease", "Non-alcoholic fatty liver disease", "Stabilizing cytochrome oxidase", "Barth syndrome" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a anti proliferative, a protein kinase inhibitor, and cancer treatment.
CC(C)N1CCC(CC(N)=O)CC1
[ "cancer treatment", "anti proliferative", "protein kinase inhibitor" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a energy storage and a proton trap for oxidative phosphorylation, it impacts tangier disease, and is smooth. The molecule is a apoptosis, emulsifier, stabilizing cytochrome oxidase, membrane stabilizer that impacts aging. The molecule is a food additive, energy source, surfactant, cholesterol translocat...
CCC(C)CCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)CC
[ "Energy storage", "Tangier disease", "Proton trap for oxidative phosphorylation", "Smooth", "Apoptosis", "Emulsifier", "Stabilizing cytochrome oxidase", "Membrane stabilizer", "Aging", "food additive", "Energy source", "surfactant", "Cholesterol translocation", "Diabetic heart disease", ...
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a nutrient, energy storage, emulsifier, energy source. The molecule is a membrane stabilizer and a surfactant, as well as must and musty.
O=C(O)/C=C/CCC(=O)O
[ "nutrient", "Energy storage", "Emulsifier", "Energy source", "Membrane stabilizer", "must", "musty", "surfactant" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, cholesterol translocation that impacts diabetic heart disease and non-alcoholic fatty liver disease. The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts tangier disease, aging, and barth syndrome.
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC
[ "Stabilizing mitochondrial structure", "Diabetic heart disease", "Proton trap for oxidative phosphorylation", "Cholesterol translocation", "Non-alcoholic fatty liver disease", "Apoptosis", "Tangier disease", "Aging", "Stabilizing cytochrome oxidase", "Barth syndrome" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a nutrient that impacts diabetes mellitus type 2, non-alcoholic fatty liver disease, alzheimer's disease, and parkinson's disease.
CCCCCC/C=C\CCCCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C[C@H]1C=CC(=O)[C@@H]1/C=C/[C@@H](O)CCCCC)COP(=O)(O)OCCN
[ "Diabetes mellitus type 2", "Non-alcoholic fatty liver disease", "nutrient", "Alzheimer's Disease", "Parkinson's disease" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a nutrient, inflammatory, energy storage that impacts atherosclerosis, pancreatitis, and thyroxine treatment. The molecule is a fat storage that impacts both obesity and metabolic syndrome. The molecule is a energy source and a membrane stabilizer, with effects on cancer and impacts on cardiovascular di...
CCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCC(C)CC
[ "nutrient", "Atherosclerosis", "inflammatory", "Energy storage", "Pancreatitis", "Thyroxine treatment", "Obesity", "Fat storage", "Metabolic syndrome", "Energy source", "Cardiovascular disease", "Membrane stabilizer", "Cancer" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is both a pi3k inhibitor and a hdac inhibitor.
CC(C)C1NC(=O)CC2C=CCCSSCC(NC1=O)C(=O)NC(Cc1ccc3ccccc3c1)C(=O)NCC(=O)O2
[ "pi3k inhibitor", "hdac inhibitor" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a anti microbial.
COc1ccc2ncc(CF)c(C(O)CCC3(CO)CCN(CCOc4cc(F)cc(F)c4F)CC3)c2c1
[ "anti microbial" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule has Distinctive odor.
CCOc1ccccc1
[ "Odor_evaluation" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a organic electroluminescent material and belongs to the electroluminescent class of molecules.
Cc1ccnc(Nc2cccc3ccccc23)c1
[ "electroluminescent", "organic electroluminescent material" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a inflammatory and membrane stabilizer, affecting cancer, and impacting metabolic syndrome, obesity, and atherosclerosis. The molecule is a nutrient and energy source, and it impacts cardiovascular disease. The molecule is a fat storage and energy storage, belonging to the thyroxine treatment class of m...
CCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C
[ "inflammatory", "Metabolic syndrome", "Obesity", "Cancer", "Atherosclerosis", "Membrane stabilizer", "Cardiovascular disease", "nutrient", "Energy source", "Fat storage", "Pancreatitis", "Thyroxine treatment", "Energy storage" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a food additive, membrane stabilizer, nutritional supplement, and nutrient, impacts diabetes mellitus type 2, and is smooth. The molecule is a emulsifier, a energy source, and a energy storage. The molecule is a surfactant that impacts non-alcoholic fatty liver disease, parkinson's disease, and alzheime...
CCCc1oc(CCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCc2oc(CCC)c(C)c2C)c(C)c1C
[ "Smooth", "food additive", "Membrane stabilizer", "Nutritional supplement", "nutrient", "Diabetes mellitus type 2", "Emulsifier", "Energy source", "Energy storage", "Non-alcoholic fatty liver disease", "surfactant", "Parkinson's disease", "Alzheimer's Disease" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a nutrient.
CC(C)=CCc1c(O)ccc2c1OC1c3ccc(O)c(CC=C(C)C)c3OCC21
[ "nutrient" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a beta-glucuronidase inhibitor, calcium channel blocker, nf-kappa-b inhibitor and belongs to the anti spasmodic class of molecules. The molecule is a mitogen-activated protein kinase inhibitor, a ec 1.14.14.14 (aromatase) inhibitor, a pesticide, and anti nociceptive. The molecule is a anti proliferant, ...
COc1cc(-c2[o+]c3cc(O)cc(O)c3cc2O)ccc1O.[Cl-]
[ "beta-glucuronidase inhibitor", "calcium channel blocker", "anti spasmodic", "NF-kappa-B inhibitor", "mitogen-activated protein kinase inhibitor", "EC 1.14.14.14 (aromatase) inhibitor", "anti nociceptive", "pesticide", "anti proliferant", "anti polio", "matrix-metalloproteinase-9 inhibitor", "...
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is anti inflammatory.
CCOC(=O)C=Cc1ccc2[nH]cc(CCc3ccccc3)c2c1
[ "anti inflammatory" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a cholesterol translocation, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts tangier disease and diabetic heart disease. The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts aging, barth syndrome, and non-alcoholic fatty liver disease.
CCCCCC/C=C\C=C/CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)C
[ "Tangier disease", "Diabetic heart disease", "Cholesterol translocation", "Stabilizing mitochondrial structure", "Proton trap for oxidative phosphorylation", "Aging", "Apoptosis", "Stabilizing cytochrome oxidase", "Barth syndrome", "Non-alcoholic fatty liver disease" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing mitochondrial structure, cholesterol translocation, proton trap for oxidative phosphorylation that impacts barth syndrome and tangier disease. The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts diabetic heart disease, non-alcoholic fatty liver disease, and aging.
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC
[ "Barth syndrome", "Stabilizing mitochondrial structure", "Cholesterol translocation", "Proton trap for oxidative phosphorylation", "Tangier disease", "Diabetic heart disease", "Non-alcoholic fatty liver disease", "Apoptosis", "Stabilizing cytochrome oxidase", "Aging" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing mitochondrial structure and a apoptosis that impacts barth syndrome, non-alcoholic fatty liver disease, and aging. The molecule is a stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, cholesterol translocation that impacts diabetic heart disease and tangier disease.
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCC
[ "Barth syndrome", "Stabilizing mitochondrial structure", "Non-alcoholic fatty liver disease", "Apoptosis", "Aging", "Stabilizing cytochrome oxidase", "Diabetic heart disease", "Proton trap for oxidative phosphorylation", "Cholesterol translocation", "Tangier disease" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing mitochondrial structure and a cholesterol translocation that impacts diabetic heart disease, non-alcoholic fatty liver disease, and aging. The molecule is a apoptosis, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts barth syndrome and tangier disease.
CCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCC(C)C
[ "Diabetic heart disease", "Stabilizing mitochondrial structure", "Non-alcoholic fatty liver disease", "Aging", "Cholesterol translocation", "Barth syndrome", "Tangier disease", "Apoptosis", "Proton trap for oxidative phosphorylation", "Stabilizing cytochrome oxidase" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, cholesterol translocation that impacts barth syndrome and aging. The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts diabetic heart disease, tangier disease, and non-alcoholic fatty liver disease.
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\CCCCCC
[ "Barth syndrome", "Aging", "Stabilizing mitochondrial structure", "Proton trap for oxidative phosphorylation", "Cholesterol translocation", "Stabilizing cytochrome oxidase", "Diabetic heart disease", "Tangier disease", "Non-alcoholic fatty liver disease", "Apoptosis" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a energy source that impacts celiac disease, inflammatory bowel disease, and heart failure. It impacts renal cell carcinoma, diabetes mellitus type 2, breast cancer, and cardiovascular disease.
CC=CCCCCCCC(O)C(=O)OC(CC(=O)[O-])C[N+](C)(C)C
[ "Celiac disease", "Inflammatory bowel disease", "Heart failure", "Energy source", "Renal cell carcinoma", "Diabetes mellitus type 2", "Breast cancer", "Cardiovascular disease" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is anti histamine.
O=S(=O)(CC(O)CCCc1cnc[nH]1)NCc1ccccc1
[ "anti histamine" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
It impacts cancer treatment.
CNC(=O)c1ncnc2c(C(C)C(C)CNc3cc(-c4ccc(F)nc4)ncn3)cccc12
[ "cancer treatment" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts non-alcoholic fatty liver disease, tangier disease, and aging. The molecule is a stabilizing mitochondrial structure, apoptosis, proton trap for oxidative phosphorylation that impacts diabetic heart disease and barth syndrome.
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC
[ "Stabilizing cytochrome oxidase", "Non-alcoholic fatty liver disease", "Tangier disease", "Aging", "Cholesterol translocation", "Stabilizing mitochondrial structure", "Diabetic heart disease", "Barth syndrome", "Apoptosis", "Proton trap for oxidative phosphorylation" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a liquid crystal and belongs to the ferroelectric class of molecules, impacting liquid crystal composition.
CCCCCCC(C)Oc1ccc(OC(=O)c2ccc(OCc3ccccc3)cc2)cc1
[ "liquid crystal composition", "liquid crystal", "ferroelectric" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a nutrient that affects both breast cancer and cervical cancer, and also impacts ulcerative colitis and atherosclerosis.
CCCCC/C=C\C/C=C\C/C=C\C=C\C(=O)CCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC
[ "nutrient", "Ulcerative colitis", "Breast cancer", "Cervical cancer", "Atherosclerosis" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, apoptosis that impacts non-alcoholic fatty liver disease and aging. The molecule is a stabilizing mitochondrial structure and a cholesterol translocation that impacts tangier disease, diabetic heart disease, and barth syndrome.
CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCCC(C)CC
[ "Stabilizing cytochrome oxidase", "Proton trap for oxidative phosphorylation", "Non-alcoholic fatty liver disease", "Aging", "Apoptosis", "Stabilizing mitochondrial structure", "Tangier disease", "Diabetic heart disease", "Cholesterol translocation", "Barth syndrome" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a energy source and fat storage, affecting cancer, and impacting thyroxine treatment, atherosclerosis, and pancreatitis. The molecule is a nutrient that impacts both cardiovascular disease and metabolic syndrome. The molecule is a inflammatory, a energy storage, and a membrane stabilizer, and it impacts...
CC(C)CCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)C
[ "Energy source", "Thyroxine treatment", "Atherosclerosis", "Cancer", "Fat storage", "Pancreatitis", "Cardiovascular disease", "Metabolic syndrome", "nutrient", "inflammatory", "Obesity", "Energy storage", "Membrane stabilizer" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a anti viral.
CCC(CC)COC(=O)C(C)NP(=O)(OCC1OC(C#N)(c2ccc3c(N)ncnn23)C2OC(C)(C)OC12)Oc1ccc2c(c1)CCCC2
[ "anti viral" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a nutrient and belongs to the thyroxine treatment class of molecules, impacting atherosclerosis. The molecule is a fat storage that impacts cardiovascular disease, metabolic syndrome, and pancreatitis.
CCCCCC/C=C\CCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCCCCCC/C=C\CCCCCCCC
[ "Atherosclerosis", "nutrient", "Thyroxine treatment", "Cardiovascular disease", "Metabolic syndrome", "Fat storage", "Pancreatitis" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a adrenergic agent, beta-adrenergic antagonist, nutrient, belonging to the anti oxidant class of molecules, with a Sharp, garlic flavor and a Garlic odor.
C=CCSSCC=C
[ "taste_evaluation", "adrenergic agent", "beta-adrenergic antagonist", "nutrient", "Odor_evaluation", "anti oxidant" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a cysteine protease inhibitor, cathepsin s inhibitor, and cathepsin inhibitor, belonging to the anti inflammatory class of molecules, and is both atherosclerosis treatment and metabolic disease treatment.
Cc1cc(-c2ccc(S(=O)(=O)C3CC(C(=O)O)N(C(=O)C4(C(F)(F)F)CC4)C3)c(C(F)(F)F)c2)ccn1
[ "cysteine protease inhibitor", "cathepsin s inhibitor", "cathepsin inhibitor", "anti inflammatory", "atherosclerosis treatment", "metabolic disease treatment" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a cholesterol translocation and a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, tangier disease, and aging. The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, apoptosis that impacts diabetic heart disease and barth syndrome.
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC
[ "Cholesterol translocation", "Stabilizing mitochondrial structure", "Non-alcoholic fatty liver disease", "Tangier disease", "Aging", "Proton trap for oxidative phosphorylation", "Stabilizing cytochrome oxidase", "Apoptosis", "Diabetic heart disease", "Barth syndrome" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a thyroxine treatment, energy source, fat storage that impacts metabolic syndrome, pancreatitis, and obesity. The molecule is a nutrient and membrane stabilizer, and it impacts atherosclerosis. The molecule is a energy storage and a inflammatory, with effects on cancer and impacts on cardiovascular dise...
CCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)C
[ "Metabolic syndrome", "Pancreatitis", "Thyroxine treatment", "Energy source", "Obesity", "Fat storage", "nutrient", "Membrane stabilizer", "Atherosclerosis", "Cancer", "Cardiovascular disease", "Energy storage", "inflammatory" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a convulsant and dopamine uptake inhibitor, belonging to both the anti spasmodic and pyrogenic classes of molecules. The molecule is a central nervous system stimulant, hyperthermic, fungicide, analgesic, and pesticide.
NC(N)=NCCS(=O)(=O)O
[ "convulsant", "dopamine uptake inhibitor", "anti spasmodic", "pyrogenic", "central nervous system stimulant", "hyperthermic", "fungicide", "analgesic", "pesticide" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a tyrosine kinase inhibitor, a anti tumor, and anti tumour.
CC1CN(c2cc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CCN1C(=O)CN
[ "tyrosine kinase inhibitor", "anti tumor", "anti tumour" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, cholesterol translocation that impacts non-alcoholic fatty liver disease and barth syndrome. The molecule is a apoptosis and a proton trap for oxidative phosphorylation that impacts tangier disease, diabetic heart disease, and aging.
CCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCC(C)C
[ "Stabilizing mitochondrial structure", "Stabilizing cytochrome oxidase", "Cholesterol translocation", "Non-alcoholic fatty liver disease", "Barth syndrome", "Tangier disease", "Apoptosis", "Proton trap for oxidative phosphorylation", "Diabetic heart disease", "Aging" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
It impacts cardiovascular disease, metabolic syndrome, and pancreatitis. The molecule is a nutrient and a fat storage, it impacts atherosclerosis, and is thyroxine treatment.
CC/C=C\C/C=C\C/C=C\C/C=C\CCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCC/C=C\CCCCCC)COC(=O)CCCCCCCCCCC/C=C\C/C=C\CCCCC
[ "Cardiovascular disease", "Metabolic syndrome", "Pancreatitis", "nutrient", "Thyroxine treatment", "Atherosclerosis", "Fat storage" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The organic electroluminescent compound class molecule influences improved driving voltage and is electroluminescent.
c1ccc(N(c2cc(N(c3ccccc3)c3cc4ccccc4c4ccccc34)c3ccc4ccccc4c3c2)c2cc3ccccc3c3ccccc23)cc1
[ "electroluminescent", "organic electroluminescent compound", "improved driving voltage" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a anti tumor agent and a mtor inhibitor, belonging to the anti tumor class of molecules.
COC1CCC(Cn2c(=O)[nH]c3ncc(-c4cnc5[nH]cc(Cl)c5c4C)cc32)OC1
[ "anti tumor", "anti tumor agent", "mtor inhibitor" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a mmp13 inhibitor.
CC(C)(C)OC(=O)Oc1cccc(-c2ccc(C(=O)O)c(Nc3cccc(O)c3)c2)c1
[ "mmp13 inhibitor" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
It impacts insulin resistance, neurodegenerative disease, and diabetes mellitus.
CCCCC/C=C\C/C=C\C/C=C\CC(O)C(O)CCCC(=O)N[C@@H](CO)[C@H](O)/C=C/CCCCCCCCCCCCC
[ "Insulin resistance", "Neurodegenerative disease", "Diabetes mellitus" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a cancer treatment.
Nc1ccc(F)cc1-c1ccc(C2=NNC(=O)CC2)cc1F
[ "cancer treatment" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a energy source and a fat storage that impacts cardiovascular disease, thyroxine treatment, obesity, and pancreatitis. The molecule is a nutrient and membrane stabilizer, and it impacts cancer. The molecule is a inflammatory and a energy storage, impacting both atherosclerosis and metabolic syndrome.
CCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCC
[ "Cardiovascular disease", "Thyroxine treatment", "Energy source", "Obesity", "Fat storage", "Pancreatitis", "Cancer", "nutrient", "Membrane stabilizer", "inflammatory", "Atherosclerosis", "Energy storage", "Metabolic syndrome" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts diabetic heart disease and aging. The molecule is a apoptosis and a cholesterol translocation that impacts non-alcoholic fatty liver disease, barth syndrome, and tangier disease.
CCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C
[ "Diabetic heart disease", "Stabilizing mitochondrial structure", "Aging", "Stabilizing cytochrome oxidase", "Proton trap for oxidative phosphorylation", "Non-alcoholic fatty liver disease", "Barth syndrome", "Apoptosis", "Tangier disease", "Cholesterol translocation" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, cholesterol translocation that impacts barth syndrome. The molecule is a apoptosis that impacts non-alcoholic fatty liver disease, aging, tangier disease, and diabetic heart disease.
CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)C
[ "Stabilizing mitochondrial structure", "Proton trap for oxidative phosphorylation", "Stabilizing cytochrome oxidase", "Cholesterol translocation", "Barth syndrome", "Non-alcoholic fatty liver disease", "Aging", "Apoptosis", "Tangier disease", "Diabetic heart disease" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a apoptosis, a nutritional supplement, and a food additive, and it impacts non-alcoholic fatty liver disease. The molecule is a emulsifier, a energy storage, and a stabilizing mitochondrial structure, it impacts tangier disease and is smooth. The molecule is a membrane stabilizer, a energy source, and a...
CCC(C)CCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C
[ "Apoptosis", "Nutritional supplement", "Non-alcoholic fatty liver disease", "food additive", "Tangier disease", "Emulsifier", "Smooth", "Energy storage", "Stabilizing mitochondrial structure", "Membrane stabilizer", "Energy source", "Diabetic heart disease", "Stabilizing cytochrome oxidase",...
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a anti bacterial drug.
CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1
[ "anti bacterial drug" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is fresh, sweet, orange peel, and fruity.
CCCCCc1cccs1
[ "fresh", "sweet", "orange peel", "fruity" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a spice that is woody and wood.
CC1C=Cc2nccnc21
[ "woody", "wood", "spice" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is pungent, sweet, and pharmaceutical. The molecule is a fragrance and a flavor, as well as green and aldehydic. The molecule is fresh, citrus, fatty, and soapy. The molecule is laundry, waxy, oil, and floral.
CCCCCC(O)CCC(O)C(O)CCCCCCCC(=O)O
[ "pungent", "sweet", "Pharmaceutical", "green", "aldehydic", "fragrance", "flavor", "fresh", "citrus", "fatty", "soapy", "laundry", "waxy", "oil", "floral" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a fat storage, energy source, membrane stabilizer that impacts obesity, cancer, and metabolic syndrome. The molecule is a energy storage that impacts both atherosclerosis and pancreatitis. The molecule is a nutrient and a inflammatory, impacting both cardiovascular disease and thyroxine treatment.
CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC(C)C
[ "Fat storage", "Obesity", "Cancer", "Energy source", "Membrane stabilizer", "Metabolic syndrome", "Energy storage", "Atherosclerosis", "Pancreatitis", "Cardiovascular disease", "nutrient", "inflammatory", "Thyroxine treatment" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a organic light-emitting device.
c1ccc(-n2c3cc4c(cc3c3cc5c6cc7c(cc6n(-c6ccccc6)c5cc32)CC7)CC4)cc1
[ "organic light-emitting device" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a nutritional supplement, a emulsifier, and a energy source, and it impacts barth syndrome. The molecule is a proton trap for oxidative phosphorylation, a energy storage, and a food additive, it impacts aging and is smooth. The molecule is a stabilizing mitochondrial structure, a apoptosis, and a stabil...
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCCCC
[ "Nutritional supplement", "Emulsifier", "Barth syndrome", "Energy source", "Proton trap for oxidative phosphorylation", "Energy storage", "Aging", "Smooth", "food additive", "Stabilizing mitochondrial structure", "Apoptosis", "Tangier disease", "Stabilizing cytochrome oxidase", "Diabetic h...
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
This molecule is a member of the electroluminescent class and influences organic electroluminescence.
c1ccc(-c2ccc(-c3nc4ccccc4n3-c3ccc(-c4ccc(-c5ccc6oc7cc8c(cc7c6c5)oc5ccccc58)cc4)cc3)cc2)cc1
[ "electroluminescent", "organic electroluminescence" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a energy storage and a cholesterol translocation, impacting both non-alcoholic fatty liver disease and aging. The molecule is a surfactant, a stabilizing cytochrome oxidase, and a emulsifier, it impacts diabetic heart disease and is smooth. The molecule is a food additive and a stabilizing mitochondrial...
CCCCCC/C=C\C=C/CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCC(C)C
[ "Energy storage", "Non-alcoholic fatty liver disease", "Aging", "Cholesterol translocation", "surfactant", "Diabetic heart disease", "Stabilizing cytochrome oxidase", "Emulsifier", "Smooth", "food additive", "Stabilizing mitochondrial structure", "Tangier disease", "Barth syndrome", "Proto...
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }